Seong Gu Heo

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Quantitative Optimization of Sensitivity and Specificity in Targeted and Whole-Exome Sequencing Using Reference-Standard DNA Mixtures

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-01-27

• Evaluation of false positive and false negative errors in targeted next generation sequencing

  Genome biology · 2025-12-01 · 4 citations

• Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

  2025-11-25

• Abstract 5057: Enhancing clinical applications by evaluation of sensitivity and specificity in whole exome sequencing

  Cancer Research · 2025-04-21

• Abstract 5058: Evaluation of false positive and false negative errors in targeted next generation sequencing

  Cancer Research · 2025-04-21

• Enhancing Clinical Applications by Evaluation of Sensitivity and Specificity in Whole Exome Sequencing

  International Journal of Molecular Sciences · 2024-12-10 · 2 citations

• Single-Cell RNA Sequencing of Circulating Myeloma Cells: Clinical Implications in Times of Immunotherapies

  Blood · 2024-11-05 · 1 citations

• Evaluation of false positive and false negative errors in targeted next generation sequencingPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2024-07-22 · 2 citations